Top Markets
#1 Islamic Coin Islamic Coin +154.29%
#2 PulseChain PulseChain +49.22%
#3 BOOK OF MEME BOOK OF MEME +30.82%
#4 RedStone RedStone +16.61%
#5 Bio Protocol Bio Protocol +15.30%
#6 edgeX edgeX +15.25%
#7 rsERG rsERG +12.23%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.05%
#9 SkyAI SkyAI +11.71%
#10 Meteora Meteora +11.27%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Classifica tra le azioni #27531
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Prezzo delle azioni
$0.343985
Ultima sincronizzazione: 2024-07-23
Capitalizzazione di mercato
$32.31M
Variazione (1 giorno)
11.88%
Variazione (1 anno)
0.00%
Paese
BE
Scambia Biocartis Group N.V. (BCART)

Categoria

Healthcare
Storico del rendimento da dividendi per Biocartis Group N.V. (BCART)
Il rendimento da dividendi (TTM) di Biocartis Group N.V. (simbolo azionario: BCART) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Biocartis Group N.V. (BCART) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
0.31%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
0.71%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
0.00%
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
0.00%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
0.00%
US